Last updated: July 30, 2026
Brompheniramine maleate is an established first-generation H1 antihistamine sold in multiple oral dosage forms and as a component of combination cold and allergy products. Publicly sourced clinical-trial activity is sparse in major registries, and there is no clear signal of late-stage (Phase 3/registration) development in the open literature. The market is characterized by generics, limited brand exclusivity, and pricing pressure.
What clinical trials exist for brompheniramine maleate right now?
Featured-snippet answer: Registries and sponsor disclosures show limited current Phase 2 to Phase 3 activity for brompheniramine maleate as a single active ingredient; most contemporary use is in marketed generics and fixed-dose combination products.
Which phases are active in registered clinical trials?
In the public domain, brompheniramine maleate’s trial footprint is historically larger than its current footprint. For a “right now” view, the observable pattern is:
- Older or completed studies on antihistamine efficacy, sedation, and comparator outcomes
- Newer studies that are more likely to be formulation, bioequivalence, or combination-product evaluations rather than stand-alone drug development
Are there ongoing Phase 3 trials that could change the market?
No clear, open-literature signal shows brompheniramine maleate in Phase 3 for a new indication or a new formulation positioned for FDA approval as a novel therapeutic.
Are bioequivalence or formulation trials still running?
Yes in principle, since generics and reformulations routinely run studies. These studies typically do not shift therapeutic market access materially, but they do sustain supply and enable product line refresh (new strengths, new combinations, alternate dosage forms).
What is the current market size and demand outlook for brompheniramine maleate?
Featured-snippet answer: Brompheniramine maleate demand tracks OTC cold and allergy self-medication and is constrained by first-generation antihistamine substitution, sedation concerns, and ongoing conversion to generics and combination products.
Where is brompheniramine maleate sold and how is it positioned?
Common commercial positioning:
- OTC (in many jurisdictions) for allergy symptoms and as an ingredient in cold medicines
- Often combined with decongestants, antitussives, analgesics, or other antihistamines depending on regional labeling rules
What drives volumes
Primary volume drivers:
- Seasonality in respiratory allergy and upper respiratory infection cycles
- Retail shelf allocation for OTC symptom relief
- Pack size strategy and pricing relative to second-generation antihistamines
What restrains growth
Key constraints:
- First-generation sedation and anticholinergic effects reduce preference versus second-generation H1 antihistamines
- Regulatory and consumer shifts toward lower-sedation options
- Competitive intensity from other antihistamines in generics and combination formats
When do brompheniramine maleate patents expire, and does exclusivity matter for this drug?
Featured-snippet answer: Exclusivity is not a primary market driver for brompheniramine maleate because it is largely generic and older in its lifecycle; current market dynamics rely on supply, labeling, and combination-product rights rather than fresh single-compound exclusivity.
How does patent expiration typically affect supply?
For molecules of this vintage, the competitive end state is usually:
- Multiple generic manufacturers with overlapping product claims
- Limited remaining patent scope tied to specific formulations, dosage strengths, or combination compositions rather than the base API
What does that mean for licensing and market entry?
Market entry is dominated by:
- Chemistry and manufacturing scale economics
- Product registration strategy by region
- Bioequivalence compliance for new SKUs
What generic and OTC entry risks exist for brompheniramine maleate?
Featured-snippet answer: Entry risks are more about regulatory and manufacturing execution than IP, since the API is established and most competition is generic.
Manufacturing and regulatory friction points
Common friction points:
- Ensuring consistent particle size and dissolution properties for oral solid dosage
- Impurity controls for saline salts and maleate salt specifications
- Labeling compliance for combination products (age groups, contraindications)
Why combination products matter
Even if the base API is widely available, combination brands can create entry timing and packaging barriers:
- Market access depends on specific co-ingredient regulatory status and labeling
- Fixed-dose combinations can have separate approvals and product-specific constraints
How do brompheniramine maleate formulations compare with other OTC antihistamines?
Featured-snippet answer: First-generation antihistamines including brompheniramine face ongoing consumer preference shifts toward second-generation agents, but they remain used in combination cold products where sedation or multi-symptom coverage is part of the label.
Oral dosage form landscape
Typical marketed options include:
- Immediate-release tablets/capsules
- Oral solutions or syrups in pediatric and combination products
Pharmacology that affects real-world selection
- Brompheniramine is more likely to cause sedation than many second-generation H1 antihistamines
- That safety profile shapes retail substitution patterns and physician/pharmacist guidance where prescription substitution is relevant
What clinical and safety outcomes matter most to regulators and payers for brompheniramine maleate?
Featured-snippet answer: Sedation, impairment risk, and anticholinergic tolerability are the primary clinical endpoints that influence labeling and consumer selection.
Safety endpoints typically evaluated
Commonly tracked measures:
- Somnolence, drowsiness, psychomotor impairment signals
- Anticholinergic symptoms (dry mouth, blurred vision, urinary retention risk in susceptible patients)
- Tolerability across elderly and pediatric age bands
How this feeds market outcomes
- Product label warnings can reduce uptake in certain consumer segments
- Pharmacovigilance influences OTC placement and marketing restrictions
What are the most likely commercial scenarios for brompheniramine maleate through 2030?
Featured-snippet answer: The base-case is steady-to-slightly declining share in pure antihistamine use, with volume stability through combination products and low-cost OTC demand. Growth is more likely in emerging-market retail channels than in share expansion in high-saturation markets.
Scenario set
-
Base case (most likely)
- API remains generic and price-competitive
- Share trends slightly down versus second-generation antihistamines
- Combination-product placements stabilize volumes
-
Downside case
- Further consumer shift to lower-sedation antihistamines
- Retail reallocation away from sedating products during seasonal peaks
-
Upside case
- New combinations with favorable labeling or pediatric-friendly formulations
- Supply expansion into regions with less saturation of second-generation alternatives
Market projection: revenue and volume outlook
Important note: A numeric market size and forecast requires a specific dataset (e.g., region, OTC classification, and whether combinations are included). The open text request does not supply those constraints, and public sources were not provided in the prompt. Under the operating constraints, no numeric forecast is issued without explicit source backing.
What can be stated with precision:
- Brompheniramine maleate is structurally positioned for stable generic supply and incremental product SKU turnover rather than major revenue step-ups tied to new clinical evidence.
- Market value is driven more by OTC category pricing, pack economics, and combination-product distribution than by breakthroughs in clinical trials.
Key takeaways
- Clinical-trial activity for brompheniramine maleate as a stand-alone late-stage development asset is limited in open registries.
- The market is generic and pricing-driven; exclusivity is not a meaningful determinant of near-term competitive dynamics.
- Demand is mostly seasonal and anchored in OTC cold/allergy self-care and combination products.
- Competitive pressure comes from second-generation antihistamines’ lower-sedation positioning.
- Through 2030, most outcomes point to volume stability via combinations and modest share pressure versus newer OTC alternatives.
FAQs
- Is brompheniramine maleate still being studied in bioequivalence trials?
- How does brompheniramine compare with cetirizine or loratadine for OTC allergy use?
- Does brompheniramine maleate face sedation-related label restrictions in major markets?
- Are combination cold products a bigger growth channel than single-ingredient brompheniramine?
- What manufacturing/quality issues most often affect generic oral antihistamine approvals?
References
- (No sources were provided in the prompt.)
